Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07916779
NA

Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle

Sponsor: University of Zurich

View on ClinicalTrials.gov

Summary

Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and has been shown to control prostate cancer as well as longer treatment schedules. Large clinical studies have demonstrated excellent cancer control rates after SBRT. Although SBRT is effective, some men experience worsening erectile function after treatment. Researchers believe that reducing radiation exposure to the nerves and blood vessels involved in erections, known as the neurovascular bundles (NVBs), may help preserve sexual function. The EF-PRESERVE study is evaluating whether a specialized MRI-guided treatment approach can safely reduce radiation dose to these structures while still delivering effective treatment to the prostate cancer.

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2026-12-01

Completion Date

2033-12-01

Last Updated

2026-11-04

Healthy Volunteers

No

Interventions

RADIATION

Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing

Patients receive daily adaptive ultra-hypofractionated SBRT (5 fractions) utilizing the ARTEMIS workflow. Before each fraction, patients undergo low-field MRI to adapt target and neurovascular bundle (NVB) contours based on daily anatomical changes. Patients are transferred in treatment position to a standard CBCT linear accelerator via a shuttle system. Radiotherapy intentionally spares the NVB (unilaterally or bilaterally depending on tumor proximity) to preserve erectile function, while ensuring the dominant intraprostatic lesion (DIL) receives at least 40Gy. Additional erection-related structures (internal pudendal artery, penile bulb, corpus cavernosum) are contoured for dosimetric analysis. Concurrent short-course ADT (not more than 6 months), if indicated, is restricted to oral GnRH antagonists (Relugolix) to allow rapid testosterone recovery.

Locations (1)

University Hospital Zurich

Zurich, Switzerland